This is the authors' abstract. We don't add key points for this paper.
Dear Editor, Sarcoidosis is a rare, multisystem granulomatous disease. While most patients are initially evaluated by primary care providers or pulmonologists, multidisciplinary collaboration is necessary to ensure accurate diagnosis and provide the best care possible for these patients. Therefore, tertiary care centers equipped with rheumatology, cardiology, dermatology, ophthalmology, neurology and pulmonology expertise are crucial for the care of systemic sarcoidosis and for research endeavors. The incidence and prevalence of sarcoidosis vary greatly by region, sex and race in the United States, with reported incidence ranges between 8 and 35.5/100 000 and prevalence ranges between 35.2 and 141.4/100 000 [1–6]. Sarcoidosis research in the United States has long emphasized disparities in Black and White populations, yet Hispanic patients remain significantly underrepresented despite comprising nearly one-fifth of the US population [7]. In fact, our literature search yielded a handful of studies (Table 1) peripherally describing incidence, prevalence, and death rates in Hispanic populations.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Francis et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: